Allarity Therapeutics Takes Action to Comply with Nasdaq Requirements
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company specializing in personalized cancer treatments, is taking significant steps to regain compliance with Nasdaq listing standards. This decision comes after a key meeting with the Nasdaq Hearings Panel, where the company secured conditional approval for a compliance plan to keep its listing.
Plan Approval and Shareholder Endorsement
During this strategic meeting, the panel approved Allarity's proposal, which included obtaining shareholder consent for a reverse stock split. This move is designed to enhance Allarity's share price and ensure it meets Nasdaq’s listing criteria. Shareholders voiced their support for this plan during the Annual Meeting, leading to the implementation of a 1-for-30 reverse stock split that took effect early today.
What the Reverse Stock Split Means
As a result of this reverse stock split, shareholders will now own one share for every thirty shares they previously held. This change is expected to help stabilize the company's stock price and rebuild investor confidence. Thomas Jensen, the CEO of Allarity Therapeutics, noted that this action will reduce the risk of delisting while allowing the company to continue its vital work in developing treatments for difficult cancers.
Commitment to Advancing Cancer Treatments
Allarity's core mission revolves around the development of stenoparib, a drug aimed at treating advanced ovarian cancer patients who have few treatment options remaining. Jensen underscored the company's dedication to pushing forward with this innovative approach to precision medicine, pointing out the encouraging results observed in clinical trials.
Stenoparib: An Innovative Cancer Treatment
Stenoparib achieves its effects by inhibiting both PARP1/2 and Tankyrase enzymes, which are vital for the survival of cancer cells. The growing acknowledgment of tankyrases as therapeutic targets underscores the innovative strategy employed by Allarity, specifically in addressing the needs of patients dealing with advanced cancer. By holding exclusive global rights to stenoparib, which was originally developed by Eisai Co. Ltd., Allarity positions itself as a significant contributor in the cancer treatment field.
Updates Following the Stock Split
The reverse stock split also brings about a new CUSIP number for Allarity’s common stock, now designated as 016744500. This change will substantially adjust the total number of outstanding shares, making the company more attractive to investors while ensuring compliance with Nasdaq regulations. Furthermore, all outstanding equity awards and shares in Allarity's 2021 equity incentive plan will be proportionally adjusted.
Steps for Shareholders After the Split
For registered stockholders, the transition to new shares after the split is quite straightforward. Those with shares in book-entry form will see their holdings automatically updated without any hassle. Shareholders who hold physical certificates will receive guidance from the designated exchange agent, Computershare Limited, on how to exchange their shares smoothly.
About Allarity Therapeutics
Allarity Therapeutics, Inc. is dedicated to delivering cutting-edge cancer treatments. Focusing on stenoparib, the company employs its proprietary DRP® companion diagnostic to enhance patient selection in ongoing clinical trials. With its headquarters in the U.S. and research facilities in Denmark, Allarity aims to address significant unmet medical needs in cancer therapy.
Frequently Asked Questions
What is the main goal of the reverse stock split?
The reverse stock split is intended to raise Allarity's stock price to align with Nasdaq's compliance requirements.
How does stenoparib function in cancer treatment?
Stenoparib is a powerful inhibitor targeting both PARP1/2 and Tankyrase enzymes, which disrupts mechanisms that allow cancer cells to survive.
Who gave the green light for the reverse stock split?
The shareholders of Allarity approved the reverse stock split at the Company's Annual Meeting.
What is the updated CUSIP number for Allarity’s stock?
The new CUSIP number for Allarity’s common stock after the split is 016744500.
How will shareholders be informed about their new shares?
Registered stockholders will have their shareholdings automatically updated, while others will receive guidance from Computershare on how to exchange their shares.
